GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (AMEX:PLX) » Definitions » E10

Protalix BioTherapeutics (Protalix BioTherapeutics) E10 : $-1.39 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Protalix BioTherapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Protalix BioTherapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.100. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.39 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 10.40% per year. During the past 5 years, the average E10 Growth Rate was 12.90% per year. During the past 10 years, the average E10 Growth Rate was 20.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Protalix BioTherapeutics was 52.90% per year. The lowest was -0.70% per year. And the median was 12.10% per year.

As of today (2024-04-27), Protalix BioTherapeutics's current stock price is $1.15. Protalix BioTherapeutics's E10 for the quarter that ended in Dec. 2023 was $-1.39. Protalix BioTherapeutics's Shiller PE Ratio of today is .


Protalix BioTherapeutics E10 Historical Data

The historical data trend for Protalix BioTherapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics E10 Chart

Protalix BioTherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.55 -1.93 -1.76 -1.73 -1.39

Protalix BioTherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.73 -1.70 -1.60 -1.54 -1.39

Competitive Comparison of Protalix BioTherapeutics's E10

For the Biotechnology subindustry, Protalix BioTherapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Shiller PE Ratio falls into.



Protalix BioTherapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protalix BioTherapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.1/129.4194*129.4194
=-0.100

Current CPI (Dec. 2023) = 129.4194.

Protalix BioTherapeutics Quarterly Data

per share eps CPI Adj_EPS
201403 -0.800 99.695 -1.039
201406 -0.700 100.560 -0.901
201409 -0.900 100.428 -1.160
201412 -0.900 99.070 -1.176
201503 -0.600 99.621 -0.779
201506 -0.500 100.684 -0.643
201509 -0.400 100.392 -0.516
201512 7.700 99.792 9.986
201603 -0.900 100.470 -1.159
201606 -1.100 101.688 -1.400
201609 -0.700 101.861 -0.889
201612 -0.200 101.863 -0.254
201703 -4.800 102.862 -6.039
201706 -0.600 103.349 -0.751
201709 -0.900 104.136 -1.119
201712 -0.870 104.011 -1.083
201803 -0.500 105.290 -0.615
201806 -0.600 106.317 -0.730
201809 -0.400 106.507 -0.486
201812 -0.400 105.998 -0.488
201903 -0.500 107.251 -0.603
201906 -0.520 108.070 -0.623
201909 -0.240 108.329 -0.287
201912 0.020 108.420 0.024
202003 0.100 108.902 0.119
202006 -0.130 108.767 -0.155
202009 -0.140 109.815 -0.165
202012 0.030 109.897 0.035
202103 -0.140 111.754 -0.162
202106 -0.250 114.631 -0.282
202109 -0.090 115.734 -0.101
202112 -0.140 117.630 -0.154
202203 -0.050 121.301 -0.053
202206 -0.110 125.017 -0.114
202209 -0.070 125.227 -0.072
202212 -0.070 125.222 -0.072
202303 -0.050 127.348 -0.051
202306 0.210 128.729 0.211
202309 -0.040 129.860 -0.040
202312 -0.100 129.419 -0.100

Add all the adjusted EPS together and divide 10 will get our e10.


Protalix BioTherapeutics  (AMEX:PLX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Protalix BioTherapeutics E10 Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Executives
Dror Bashan director, officer: President and CEO 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 L3 20100
Eliot Forster director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Aharon Schwartz director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Zvi Shmuel Ben director 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 2161401
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Eyal Rubin officer: Sr. VP and CFO C/O BRAINSTORM CELL THERAPEUTICS INC.,, 3 UNIVERSITY PLAZA DRIVE, STE 320, HACKENSACK NJ 07601
Yaron Naos officer: Sr. VP, Operations 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 20100
Yael Hayon officer: Vice President, R&D 2 SNUNIT STREET, SCIENCE PARK, POB 455, CARMIEL L3 2161401
Zeev Bronfeld director 6 URI STREET, TEL AVIV L3 64954
Amos Bar-shalev director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
David Granot director 6225 NEIL ROAD, RENO NV 89511
Pol F Boudes director C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Gwen A Melincoff director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Moshe Manor officer: President & CEO C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100

Protalix BioTherapeutics (Protalix BioTherapeutics) Headlines